WIPO logo
Mobile | Deutsch | Español | Français | 日本語 | 한국어 | Português | Русский | 中文 | العربية |
PATENTSCOPE

Search International and National Patent Collections
World Intellectual Property Organization
Search
 
Browse
 
Translate
 
Options
 
News
 
Login
 
Help
 
Machine translation
1. (WO2015121688) BIOMARKERS AND THERAPEUTIC TARGETS FOR SARCOMA
Latest bibliographic data on file with the International Bureau   

Pub. No.:    WO/2015/121688    International Application No.:    PCT/GB2015/050450
Publication Date: 20.08.2015 International Filing Date: 17.02.2015
IPC:
C07K 16/28 (2006.01), C12Q 1/68 (2006.01), G01N 33/574 (2006.01), A61K 39/395 (2006.01), A61P 35/00 (2006.01)
Applicants: OXFORD UNIVERSITY INNOVATION LIMITED [GB/GB]; Buxton Court 3 West Way Botley Oxford OX2 0SZ (GB)
Inventors: RABBITTS, Terence; (GB).
TOWN, Jennifer; (GB).
PAIS, Helio; (GB)
Agent: BOULT WADE TENNANT; Verulam Gardens 70 Grays Inn Road London Greater London WC1X 8BT (GB)
Priority Data:
1402771.8 17.02.2014 GB
Title (EN) BIOMARKERS AND THERAPEUTIC TARGETS FOR SARCOMA
(FR) BIOMARQUEURS ET CIBLES THÉRAPEUTIQUES POUR LE SARCOME
Abstract: front page image
(EN)New sarcoma cell surface targets have been identified and include LINGO-1, KCNN1 and CDH23. Specific binding agents that specifically bind to these targets include antibodies and aptamers. Methods of treating sarcoma utilize the specific binding agents. Methods of diagnosing and detecting sarcoma, including metastases and residual disease involve determining the expression of LINGO-1, KCNN1 and CDH23.
(FR)L'invention concerne de nouvelles cibles à la surface des cellules du sarcome, qui ont été identifiées et contiennent LINGO-1, KCNN1 et CDH23. Des agents de liaison spécifiques qui se lient de manière spécifique à ces cibles contiennent des anticorps et des aptamères. L'invention concerne des procédés de traitement du sarcome ayant recours aux agents de liaison spécifiques. L'invention concerne enfin des procédés de diagnostic et de détection du sarcome, y compris des métastases et des maladies résiduelles, comprenant la détermination de l'expression de LINGO-1, KCNN1 et CDH23.
Designated States: AE, AG, AL, AM, AO, AT, AU, AZ, BA, BB, BG, BH, BN, BR, BW, BY, BZ, CA, CH, CL, CN, CO, CR, CU, CZ, DE, DK, DM, DO, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, HN, HR, HU, ID, IL, IN, IR, IS, JP, KE, KG, KN, KP, KR, KZ, LA, LC, LK, LR, LS, LU, LY, MA, MD, ME, MG, MK, MN, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, OM, PA, PE, PG, PH, PL, PT, QA, RO, RS, RU, RW, SA, SC, SD, SE, SG, SK, SL, SM, ST, SV, SY, TH, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, ZA, ZM, ZW.
African Regional Intellectual Property Organization (BW, GH, GM, KE, LR, LS, MW, MZ, NA, RW, SD, SL, ST, SZ, TZ, UG, ZM, ZW)
Eurasian Patent Organization (AM, AZ, BY, KG, KZ, RU, TJ, TM)
European Patent Office (AL, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LT, LU, LV, MC, MK, MT, NL, NO, PL, PT, RO, RS, SE, SI, SK, SM, TR)
African Intellectual Property Organization (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, KM, ML, MR, NE, SN, TD, TG).
Publication Language: English (EN)
Filing Language: English (EN)